


Data Sheet

Product Name:	Valiltramiprosate
Cat. No.:	CS-0064594
CAS No.:	1034190-08-3
Molecular Formula:	C ₈ H ₁₈ N ₂ O ₄ S
Molecular Weight:	238.30
Target:	Amyloid-β
Pathway:	Neuronal Signaling
Solubility:	H ₂ O : 30 mg/mL (125.89 mM; ultrasonic and warming and heat to 60°C)



BIOLOGICAL ACTIVITY:

ALZ-801 is a potent and orally available small-molecule **β-amyloid (Aβ)** anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound^[1]. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer's disease^[2]. IC₅₀ & Target:β-amyloid^[1] **In Vivo:** ALZ-801 (oral administration; 172 mg/kg; single dose) exhibits mean AUC_t values of 58,758 and 5841 ng/mL.h in plasma and brain, respectively. The ALZ-801: Tramiprosate ratio in plasma and brain is 1.8 and 3.1, respectively in male CD-1 mice^[1].

References:

[1]. John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9): 849–861.

[2]. Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333.

CAIndexNames:

1-Propanesulfonic acid, 3-[[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-

SMILES:

O=S(CCCNC([C@@H](N)C(C)C)=O)(O)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA